Drug Trial Radar · NCT06930612
A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis (NEZHA-1)
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
120
Actual
Start
Jun 12, 2025
Primary completion
Apr 20, 2026
Study completion Jul 10, 2026
Sponsor
- Lead sponsor
- Beijing Keymed Biosciences Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized, double blind, placebo-controlled Phase II study to evaluate the efficacy and safety of CM512, and to observe the life quality of subjects, the Pharmacokinetics, Pharmacodynamics and immunogenicity of CM512 in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP).
Conditions
- Chronic Rhinosinusitis With Nasal Polyposis
Interventions
CM512Biological
Administered subcutaneous injection
PlaceboDrug
Administered subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Nasal Polyps Score (NPS)Time frame: at week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tong-Ren hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.